GET DAILY SIGNALSRocket Pharmaceuticals (RCKT) Q3 2026 Earnings Preview: Loss Estimates and Danon Disease Updates
Key Takeaways
- Rocket Pharmaceuticals (RCKT) is expected to report Q3 2026 results around early November 2026, with a consensus loss estimate of -$0.39 per share.
- Revenue expectations remain negligible — roughly $0.2 million — reflecting the company's early-commercial, largely pre-revenue stage.
- The prior-year comparison is a net loss of -$0.45 per share in Q3 2025, making the year-over-year loss trend a key focus.
- Investor attention centers on the FDA-aligned pivotal Phase 2 trial of RP-A501 for Danon disease, the company's lead cardiovascular gene therapy program.
- A recently secured $150 million credit facility from Hercules Capital strengthens the balance sheet and supports the clinical pipeline.
- Rocket has beaten consensus earnings-per-share (EPS) estimates in six of its last eight quarters, though most of these were loss-per-share beats.
- For more on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
- Discover Trending AI Robots for data-driven trading ideas across the market.
Why This Earnings Report Matters
Rocket Pharmaceuticals is a commercial-stage biotechnology company advancing gene therapies for rare, life-threatening diseases, with a strategic focus on inherited cardiovascular disorders. Its pipeline is anchored by RP-A501, an adeno-associated virus (AAV) gene therapy in a pivotal Phase 2 trial for Danon disease. Because the company generates little to no product revenue, the quarterly earnings release matters less for top-line results and more for clinical progress, cash runway, and spending discipline. Investors closely track research and development (R&D) expense trends, restructuring savings, and management commentary on regulatory milestones. Following a strategic reorganization that cut operating expenses by roughly 25%, this report will signal whether the leaner cost structure is holding while the pivotal Danon disease program advances toward key data and potential regulatory milestones. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Rocket Pharmaceuticals to report a net loss of approximately -$0.39 per share for the third quarter of 2026, compared with a loss of -$0.45 per share in the same period a year earlier. Consensus revenue is minimal at around $0.2 million, consistent with a company that has not yet achieved meaningful commercial sales. These figures should be viewed with caution, however: the prior quarter (Q2 2026) produced a headline EPS of $1.08 that was driven by a large one-time item rather than operating income, underscoring how non-operating gains can distort quarter-to-quarter comparisons. Investors will focus instead on core operating loss, R&D spending, and cash balances. Rocket has beaten consensus EPS in six of the past eight quarters, though historically these have been loss-per-share beats with limited top-line impact.
Market Reaction and Investor Sentiment
Sentiment heading into Rocket Pharmaceuticals' Q3 2026 report has been mixed but cautiously improving. The stock has traded in a low single-digit range, reflecting the market's wait-and-see posture on the Danon disease program. On the positive side, the company secured FDA alignment in September 2026 on the path to complete the pivotal Phase 2 trial of RP-A501, a milestone that triggered several analyst actions, including upgrades from Needham and Goldman Sachs and reaffirmed Outperform-style ratings from firms such as Cantor Fitzgerald. Conversely, the shares carry elevated risk because the pivotal trial remains ongoing and the company is not yet generating material revenue. Key risk factors heading into the print include any unexpected increase in R&D expenses, dilution from financing activity, or delays in clinical enrollment and dosing under the modified protocol.
Forward Outlook and Key Factors to Monitor
Following the Q3 2026 report, investors should watch the Danon disease program most closely. The company has aligned with the FDA on a 12-patient pivotal efficacy population and 12-month co-primary endpoints for RP-A501, and the pace of enrollment and dosing will be a central narrative. Any updated safety or efficacy signals from the pivotal trial, or from longer-term Phase 1 follow-up, could materially shift sentiment.
Cash runway is the second key factor. As of late 2025, Rocket estimated its resources could fund operations into the second quarter of 2027, and the new $150 million credit facility from Hercules Capital — with an initial $35 million tranche — provides additional flexibility. Investors will want to see that spending remains disciplined while the company funds its lead cardiovascular programs.
Finally, monitor the broader pipeline. Rocket has de-prioritized its Fanconi Anemia and Pyruvate Kinase Deficiency programs to concentrate resources on its AAV cardiovascular platform, including RP-A601 for PKP2-ACM (a heart muscle condition) and RP-A701 for BAG3-DCM (dilated cardiomyopathy). The lentiviral candidate KRESLADI for severe leukocyte adhesion deficiency-I (LAD-I) also remains in play following a Biologics License Application (BLA) resubmission. Progress on any of these fronts, combined with stable cash management, will shape the next leg of the story.
Integrating AI Tools into My Research Process
When evaluating names like RCKT alongside other biotech peers, I frequently rely on Tickeron’s AI Screener to apply technical and fundamental filters quickly. This approach helps surface relevant comparables and trend signals without spending hours on manual scans, which keeps my focus on the clinical and financial details that matter most for these early-stage companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for RCKT turns positive, indicating new upward trend
RCKT saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 66 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 30 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for RCKT just turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 201 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.725) is normal, around the industry mean (2.904). P/E Ratio (-15.219) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of gene therapy services
Industry Biotechnology
Advertisement